Antenatal magnesium sulphate administration for fetal neuroprotection : a French national survey
BACKGROUND: Magnesium sulphate (MgSO4) is the only treatment approved for fetal neuroprotection. No information on its use is available in the absence of a national registry of neonatal practices. The objective of our study was to evaluate the use of MgSO4 for fetal neuroprotection in French tertiary maternity hospitals (FTMH).
METHODS: Online and phone survey of all FTMH between August 2014 and May 2015. A participation was expected from one senior obstetrician, one senior anaesthetist and one senior neonatologist from each FTMH. Information was obtained from 63/63 (100%) FTMH and 138/189 (73%) physicians. Use of MgSO4 for fetal neuroprotection, regimen and injection protocols, reasons for non-use were the main outcome measures.
RESULTS: 60.3% of FTMH used MgSO4 for fetal neuroprotection. No significant difference was observed between university and non-university hospitals or according to the annual number of births. Protocols differed especially in terms of the maximum gestational age (3% <28 WG, 71% <33 WG, 18% <34 WG and 8% < 35 WG). Eighty seven percent of centers using MgSO4 prescribed retreatment when necessary, but according to non-consensual modalities in terms of number of treatments or between-treatment intervals. Injections and monitoring were mostly performed in the delivery room (97%) but also in the recovery room in one half of hospitals. Lack of experience (52%), absence of a written protocol (49%) and national guidelines (46%) were the reasons most commonly reported to explain non-use of MgSO4 as a neuroprotective agent.
CONCLUSIONS: Sixty percent of FTMH used MgSO4 for fetal neuroprotection, but according to heterogeneous regimens. National guidelines could allow standardization of practices and better MgSO4 coverage.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2017 |
|---|---|
| Erschienen: |
2017 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:17 |
|---|---|
| Enthalten in: |
BMC pregnancy and childbirth - 17(2017), 1 vom: 13. Sept., Seite 304 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Chollat, Clément [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
7487-88-9 |
|---|
| Anmerkungen: |
Date Completed 30.05.2018 Date Revised 13.11.2018 published: Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1186/s12884-017-1489-z |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM275745414 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM275745414 | ||
| 003 | DE-627 | ||
| 005 | 20231225010401.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2017 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1186/s12884-017-1489-z |2 doi | |
| 028 | 5 | 2 | |a pubmed24n0919.xml |
| 035 | |a (DE-627)NLM275745414 | ||
| 035 | |a (NLM)28903747 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Chollat, Clément |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Antenatal magnesium sulphate administration for fetal neuroprotection |b a French national survey |
| 264 | 1 | |c 2017 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 30.05.2018 | ||
| 500 | |a Date Revised 13.11.2018 | ||
| 500 | |a published: Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a BACKGROUND: Magnesium sulphate (MgSO4) is the only treatment approved for fetal neuroprotection. No information on its use is available in the absence of a national registry of neonatal practices. The objective of our study was to evaluate the use of MgSO4 for fetal neuroprotection in French tertiary maternity hospitals (FTMH) | ||
| 520 | |a METHODS: Online and phone survey of all FTMH between August 2014 and May 2015. A participation was expected from one senior obstetrician, one senior anaesthetist and one senior neonatologist from each FTMH. Information was obtained from 63/63 (100%) FTMH and 138/189 (73%) physicians. Use of MgSO4 for fetal neuroprotection, regimen and injection protocols, reasons for non-use were the main outcome measures | ||
| 520 | |a RESULTS: 60.3% of FTMH used MgSO4 for fetal neuroprotection. No significant difference was observed between university and non-university hospitals or according to the annual number of births. Protocols differed especially in terms of the maximum gestational age (3% <28 WG, 71% <33 WG, 18% <34 WG and 8% < 35 WG). Eighty seven percent of centers using MgSO4 prescribed retreatment when necessary, but according to non-consensual modalities in terms of number of treatments or between-treatment intervals. Injections and monitoring were mostly performed in the delivery room (97%) but also in the recovery room in one half of hospitals. Lack of experience (52%), absence of a written protocol (49%) and national guidelines (46%) were the reasons most commonly reported to explain non-use of MgSO4 as a neuroprotective agent | ||
| 520 | |a CONCLUSIONS: Sixty percent of FTMH used MgSO4 for fetal neuroprotection, but according to heterogeneous regimens. National guidelines could allow standardization of practices and better MgSO4 coverage | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Magnesium sulphate | |
| 650 | 4 | |a National survey | |
| 650 | 4 | |a Neonatology | |
| 650 | 4 | |a Neuroprotection | |
| 650 | 4 | |a Very preterm infants | |
| 650 | 7 | |a Calcium Channel Blockers |2 NLM | |
| 650 | 7 | |a Neuroprotective Agents |2 NLM | |
| 650 | 7 | |a Magnesium Sulfate |2 NLM | |
| 650 | 7 | |a 7487-88-9 |2 NLM | |
| 700 | 1 | |a Le Doussal, Lise |e verfasserin |4 aut | |
| 700 | 1 | |a de la Villéon, Gaëlle |e verfasserin |4 aut | |
| 700 | 1 | |a Provost, Delphine |e verfasserin |4 aut | |
| 700 | 1 | |a Marret, Stéphane |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t BMC pregnancy and childbirth |d 2001 |g 17(2017), 1 vom: 13. Sept., Seite 304 |w (DE-627)NLM112808085 |x 1471-2393 |7 nnns |
| 773 | 1 | 8 | |g volume:17 |g year:2017 |g number:1 |g day:13 |g month:09 |g pages:304 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1186/s12884-017-1489-z |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 17 |j 2017 |e 1 |b 13 |c 09 |h 304 | ||